Print Article Download PDF

Alzheimer’s Disease Research Center (ADRC)

In April 2004, UCSF was designated as a national Alzheimer’s Disease Research Center (ADRC) with the Memory and Aging Center as the central coordinating site. Funded by the NIH, this large collaborative project involves multiple institutions and locations. It is designed to integrate basic science and clinical resources in order to investigate the clinical, molecular, neuropathological and neuroimaging features of Alzheimer’s disease (AD), non-AD dementias and mild cognitive impairment (MCI).

The ADRC has two overarching aims:

  1. To bridge the gap between laboratory and clinical studies in dementia and aging, and
  2. To explore the unique and overlapping symptoms seen in various neurodegenerative diseases.

The ADRC uses standardized and novel methods to examine patients and biological specimens, so that new hypotheses can be tested regarding the cause, diagnosis and treatment of dementia. The ADRC brings together investigators at various locations who are leaders in basic science and clinical research related to dementia. The core project is New Approaches to Dementia Heterogeneity.

California Alzheimer’s Disease Center (CADC)

In 1984, the State of California established the California Alzheimer’s Disease Program (ADP) through legislation that sought to:

  1. Improve health care delivery to persons affected by Alzheimer’s disease and their caregivers
  2. Provide training and education to health care professionals, students, patients, caregivers and community
  3. Advance diagnosis and treatment of Alzheimer’s disease and related disorders (ADRD).

To carry out this mandate, the Alzheimer’s Disease Program established a network of ten dementia care Centers of Excellence at California medical schools. These California Alzheimer’s Disease Centers (CADCs) effectively and efficiently improve AD health care delivery, provide specialized training and education to health care professionals and others, and advance the diagnosis and treatment of AD.

Global Brain Health Institute (GBHI)

The goal of the Global Brain Health Institute is to identify and mentor outstanding individuals who want to make a lasting impact on brain health in their communities and globally. The collaboration is co-directed by internationally recognized leaders the University of California, San Francisco (UCSF) and Trinity College, Dublin (TCD). By nurturing and developing the next generation of global health scholars with expertise in brain protection, neuroscience, dementia and public policy, we hope to reduce the scale and impact of dementia across the world.

Consortium for Frontotemporal Dementia Research (CFR)

The Consortium for Frontotemporal Dementia Research (CFR) is a UCSF-based consortium established to accelerate research of frontotemporal dementia (FTD). Initial funding for the CFR comes from private donations and The Bluefield Project. The CFR was created to combine the power of this funding with collaborative science by the best minds in the field to find a cure for FTD related to progranulin mutations within 10 years.

Tau Consortium

The Tau Consortium is a group of international clinician-scientists working together to understand, and ultimately treat and cure, tau-related disorders (tauopathies) including progressive supranuclear palsy (PSP), frontotemporal dementia with parkinsonism (FTD-P), corticobasal degeneration (CBD) and chronic traumatic encephalopathy (CTE). The consortium is studying the tau (MAPT) gene to understand how various changes in the gene lead to neurodegeneration.